Exploring options for Asia market: Stemcell United Ltd (ASX: SCU) reported their signing of a Letter Agreement with iCAN Israel-Cannabis to negotiate and execute a mutually agreeable licensing and services agreement. ICAN would offer services to the group with respect to their business operations in Asia. Moreover, an investment agreement would be made with the group for over 5% to 10% stake in ICAN, subject to due diligence. The group believes that iCAN end to end services would boost their capabilities and scope of business in Medical Cannabis field. ICAN would assert to an idea germination development and review through clinical trials and importantly the medical delivery systems; as well as the appropriate marketing and branding. If the deal is signed, the will be able to expand their services in Asia market. Meanwhile, Stemcell United reported their initial revenue from sale of dendrobium product in the last quarter and started marketing of their dendrobium essence infused mask this quarter. Moreover, the group is also in discussion with a Chinese Pharmaceutical firm on offering consultancy services for manufacturing resins. Stemcell United is planning to strengthen their capital position and intends to issue up to 25 million ordinary shares at $0.10 per share to sophisticated investors. The group intends to use these funds for their working capital and developments like scaling up dendrobium business and exploring opportunities in Cannabis business. SCU would get shareholder approval if the issue of the shares exceeds the 15% capacity.
To read the complete report CLICK HERE. To get your free report CLICK HERE
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.